In:
Obstetric Anesthesia Digest, Ovid Technologies (Wolters Kluwer Health), Vol. 41, No. 2 ( 2021-06), p. 77-78
Abstract:
( Am J Obstet Gynecol . 2020;223:433.e1–14) Placenta accreta spectrum (PAS), which includes placenta accreta, placenta increta and placenta percreta, often leads to hysterectomy and large-volume maternal hemorrhage and is a major cause of maternal mortality and morbidity. While maternal outcomes can be improved with planning after an accurate diagnosis, more than 50% of pregnancies complicated by PAS are not diagnosed prior to delivery. A method of reliable, early diagnosis of PAS is needed to improve maternal outcomes. This study used a novel aptamer-based platform for biomarker discovery to explore whether women who experience PAS have a unique protein signature in maternal plasma during the third trimester that may be used to diagnose PAS.
Type of Medium:
Online Resource
ISSN:
0275-665X
DOI:
10.1097/01.aoa.0000744112.29802.a7
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2021
detail.hit.zdb_id:
2071164-5
Permalink